Keystone Financial Services Buys New Shares in IQVIA Holdings Inc. $IQV

Keystone Financial Services purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,298 shares of the medical research company’s stock, valued at approximately $205,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Verdence Capital Advisors LLC acquired a new stake in shares of IQVIA during the 2nd quarter worth $3,612,000. Patton Fund Management Inc. purchased a new stake in IQVIA during the second quarter valued at about $231,000. Heritage Investors Management Corp increased its stake in IQVIA by 10.5% during the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock worth $16,500,000 after acquiring an additional 9,909 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after purchasing an additional 566 shares during the period. Finally, Nordea Investment Management AB grew its holdings in shares of IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.2%

Shares of NYSE IQV opened at $210.50 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $225.00. The stock’s 50-day simple moving average is $199.38 and its 200-day simple moving average is $176.07. The firm has a market cap of $35.85 billion, a price-to-earnings ratio of 28.88, a PEG ratio of 2.36 and a beta of 1.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the business posted $2.84 earnings per share. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday. TD Cowen downgraded IQVIA from a “buy” rating to a “hold” rating and increased their price target for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Finally, Stifel Nicolaus boosted their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $239.94.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.